Virtu Financial LLC Makes New $95,000 Investment in Vascular Biogenics Ltd. (NASDAQ:VBLT)

Virtu Financial LLC bought a new position in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) during the 2nd quarter, Holdings Channel.com reports. The firm bought 39,618 shares of the biopharmaceutical company’s stock, valued at approximately $95,000.

Other institutional investors have also bought and sold shares of the company. Squarepoint Ops LLC acquired a new position in Vascular Biogenics during the first quarter worth $229,000. LPL Financial LLC increased its position in Vascular Biogenics by 110.8% during the second quarter. LPL Financial LLC now owns 101,176 shares of the biopharmaceutical company’s stock worth $242,000 after buying an additional 53,176 shares during the last quarter. Millennium Management LLC acquired a new position in Vascular Biogenics during the second quarter worth $89,000. Goldman Sachs Group Inc. increased its position in Vascular Biogenics by 44.1% during the second quarter. Goldman Sachs Group Inc. now owns 16,556 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 5,069 shares during the last quarter. Finally, Telemetry Investments L.L.C. increased its position in Vascular Biogenics by 42.1% during the second quarter. Telemetry Investments L.L.C. now owns 152,764 shares of the biopharmaceutical company’s stock worth $365,000 after buying an additional 45,264 shares during the last quarter. 6.15% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ:VBLT opened at $2.20 on Thursday. The company has a market cap of $137.21 million, a P/E ratio of -4.31 and a beta of 1.11. The stock’s 50-day moving average is $2.23 and its 200-day moving average is $2.26. Vascular Biogenics Ltd. has a 52-week low of $1.18 and a 52-week high of $3.17.

Vascular Biogenics (NASDAQ:VBLT) last issued its quarterly earnings results on Monday, November 15th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.02. Vascular Biogenics had a negative return on equity of 69.23% and a negative net margin of 3,546.69%. During the same period in the prior year, the company earned ($0.12) EPS. Research analysts predict that Vascular Biogenics Ltd. will post -0.44 EPS for the current fiscal year.

VBLT has been the topic of several research analyst reports. Zacks Investment Research raised Vascular Biogenics from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a research report on Friday, November 19th. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Vascular Biogenics in a research report on Tuesday, November 16th. Five analysts have rated the stock with a buy rating, According to MarketBeat, Vascular Biogenics presently has a consensus rating of “Buy” and a consensus target price of $5.10.

Vascular Biogenics Profile

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of first-in-class treatments for cancer. Its programs include cancer, inflammation, and VB-600 which are focused on treating tumors, ovarian cancer, and chronic immune-related indications.

Featured Story: What is an economic bubble?

Want to see what other hedge funds are holding VBLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vascular Biogenics Ltd. (NASDAQ:VBLT).

Institutional Ownership by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.